![Immunocytochemistry/Immunofluorescence: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] - ICC/IF staining of 3 tissue arrays with 104 invasive ductal carcinoma tissue sections with metastatic carcinomas, 21 invasive ductal carcinoma tissue sections, & 8 normal tissue sections. 33 carcinoma tissue sections were -ve for estrogen & progesterone receptor; don't overexpress Her2neu receptor (triple negative breast cancer, TNBC). (A) Cyr61/CCN1 and/or S100A4 expression analysis in 123 invasive ductal carcinoma tissue & lymph node sections of 104 patients (B); representative ICC/IF stains analyzed with 100x oil objective. (C) From 123 invasive ductal carcinomas tissue sections, 33 stated as being TNBC. (D) Normal breast tissue sections (n = 8) analyzed for Cyr61/CCN1 and/ or S100A4 expression using ICC/IF. Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fonc.2019.01074/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-[DyLight-550]-Immunocytochemistry-Immunofluorescence-NB100-356R-img0001.jpg "Immunocytochemistry/Immunofluorescence: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] - ICC/IF staining of 3 tissue arrays with 104 invasive ductal carcinoma tissue sections with metastatic carcinomas, 21 invasive ductal carcinoma tissue sections, & 8 normal tissue sections. 33 carcinoma tissue sections were -ve for estrogen & progesterone receptor; don't overexpress Her2neu receptor (triple negative breast cancer, TNBC). (A) Cyr61/CCN1 and/or S100A4 expression analysis in 123 invasive ductal carcinoma tissue & lymph node sections of 104 patients (B); representative ICC/IF stains analyzed with 100x oil objective. (C) From 123 invasive ductal carcinomas tissue sections, 33 stated as being TNBC. (D) Normal breast tissue sections (n = 8) analyzed for Cyr61/CCN1 and/ or S100A4 expression using ICC/IF. Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fonc.2019.01074/full), licensed under a CC-BY license.")
| Reactivity | Hu, Mu, RbSpecies Glossary |
| Applications | WB, Simple Western, ICC/IF, IHC, B/N |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | DyLight 550 |
| Immunogen | A synthetic peptide made to the human CYR61 protein sequence (between residues 150-250). [UniProt# O00622] |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | CCN1 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Application Notes | Optimal dilution of this antibody should be experimentally determined. |
|
| Publications |
|
| Storage | Store at 4C in the dark. |
| Buffer | 50mM Sodium Borate |
| Preservative | 0.05% Sodium Azide |
| Purity | Immunogen affinity purified |
![Western Blot AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/Akt3_AF887_Western_Blot_5930.jpg)
![Simple Western AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/16332.jpg)
![Intracellular Staining by Flow Cytometry AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/Akt3_AF887_Flow_Cytometry_8283.jpg)
![Immunocytochemistry FosB/G0S3 Antibody [Unconjugated]](https://images.novusbio.com/images2/FosB_AF2214_Immunocytochemistry__Immunofluorescence_21634.jpg)
![Immunohistochemistry FosB/G0S3 Antibody [Unconjugated]](https://images.novusbio.com/images2/FosB_AF2214_Immunohistochemistry_9938.jpg)
| Publication using NB100-356R | Applications | Species |
|---|---|---|
| Hellinger JW, HUchel S, Goetz L et al. Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion Front Oncol. 2019-10-23 [PMID: 31709177] (Human) Details: Citation used the Alexa Fluor 488 format of this antibody. |
Human |
Secondary Antibodies |
Isotype Controls |
Research Areas for Cyr61/CCN1 Antibody (NB100-356R)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | CCN1 |
![Western Blot: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] - ERK1/2 activity is transducer of CYR61 mediated S100A4 regulation. (A) Scheme illustrating hypothesis of CYR61 regulating S100A4 in a p-ERK1/2 dependent manner. (B) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) expression in different breast cancer cell lines detected by western blotting. (C) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) & CYR61 expression in different breast cancer cell lines after transient CYR61 transfection detected by western blotting. (D) Relative S100A4 expression of invasive breast cancer cell lines treated with 10 μM U0126 compared to DMSO controls. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. n = 3; *P < 0.05;**P < 0.01;***P < 0.005 (E) 3D invasion analysis of breast cancer spheroids seeded after U0126 treatment. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection & compared to spheroid area at time point 0 (adding of Matrigel + 10 μM U0126). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. MCF-7-EMT n = 6; T47D-EMT n = 5; MDA-MB-231 n = 6; HCC1806 n = 5; **P < 0.01;***P < 0.005;****P < 0.0001 (F) Analysis of relative AlamarBlue reduction as indicator for cell viability. Breast cancer cell spheroids were grown & AlamarBlue reduction was assessed 48 h after adding Matrigel & 10 μM U0126 at 4 h incubation. Relative AlamarBlue reduction was calculated compared to DMSO control spheroids. Data represent mean ± SEM. MCF-7-EMT n = 3; T47D-EMT n = 4; MDA-MB-231 n = 3; HCC1806 n = 3; *P < 0.05;**P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31709177), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-356r_rabbit-polyclonal-cyr61-ccn1-antibody-dylight-550-31020241553202.jpg "Western Blot: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] - ERK1/2 activity is transducer of CYR61 mediated S100A4 regulation. (A) Scheme illustrating hypothesis of CYR61 regulating S100A4 in a p-ERK1/2 dependent manner. (B) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) expression in different breast cancer cell lines detected by western blotting. (C) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) & CYR61 expression in different breast cancer cell lines after transient CYR61 transfection detected by western blotting. (D) Relative S100A4 expression of invasive breast cancer cell lines treated with 10 μM U0126 compared to DMSO controls. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. n = 3; *P < 0.05;**P < 0.01;***P < 0.005 (E) 3D invasion analysis of breast cancer spheroids seeded after U0126 treatment. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection & compared to spheroid area at time point 0 (adding of Matrigel + 10 μM U0126). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. MCF-7-EMT n = 6; T47D-EMT n = 5; MDA-MB-231 n = 6; HCC1806 n = 5; **P < 0.01;***P < 0.005;****P < 0.0001 (F) Analysis of relative AlamarBlue reduction as indicator for cell viability. Breast cancer cell spheroids were grown & AlamarBlue reduction was assessed 48 h after adding Matrigel & 10 μM U0126 at 4 h incubation. Relative AlamarBlue reduction was calculated compared to DMSO control spheroids. Data represent mean ± SEM. MCF-7-EMT n = 3; T47D-EMT n = 4; MDA-MB-231 n = 3; HCC1806 n = 3; *P < 0.05;**P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31709177), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunohistochemistry CTGF/CCN2 Antibody [Unconjugated] - C-terminus](https://images.novusbio.com/images2/CTGF_AF660_Immunohistochemistry_9968.jpg)
![Immunohistochemistry CTGF/CCN2 Antibody [Unconjugated] - C-terminus](https://images.novusbio.com/images2/CTGF_AF660_Immunohistochemistry_9969.jpg)
![Western Blot CTGF/CCN2 Antibody [Unconjugated] - C-terminus](https://images.novusbio.com/images/af660_human-ctgf-ccn2-c-terminus-affinity-purified-polyclonal-ab-822024951141.jpg)
![Immunohistochemistry NOV/CCN3 Antibody [Unconjugated]](https://images.novusbio.com/images2/NOV_AF1640_Immunohistochemistry_7314.jpg)
![Immunohistochemistry Plexin A1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Plexin_A1_AF4309_Immunohistochemistry_10417.jpg)
![Immunocytochemistry Plexin A1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Plexin_A1_AF4309_Immunocytochemistry_11095.jpg)
![Western Blot Plexin A1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Plexin_A1_AF4309_Western_Blot_9601.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/DATA_VEGF_DVE00_ELISA_871.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/DATA_VEGF_DVE00_ELISA_872.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/VEGF_DVE00_ELISA_208.jpg)
![Western Blot c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Western_Blot_18923.jpg)
![Immunocytochemistry c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Immunocytochemistry__Immunofluorescence_18945.jpg)
![Simple Western c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Simple_Western_19175.jpg)
![Western Blot ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Western_Blot_5097.jpg)
![Immunohistochemistry ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Immunohistochemistry_20696.jpg)
![Knockout Validated ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Knockout_Validated_22864.jpg)
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![Integrin alpha V beta 3 [Unconjugated]](/sites/all/modules/enterprise-tech/et_datasheets/images/novus_guarantee.png "Integrin alpha V beta 3 [Unconjugated]")
![N/A IL-6 [HRP]](https://images.novusbio.com/images2/DATA_IL6_M6000_ELISA_936.jpg)
![N/A IL-6 [HRP]](https://images.novusbio.com/images2/IL-6_M6000_ELISA_415.jpg)
![N/A IL-6 [HRP]](https://images.novusbio.com/images/m6000b_mouse-il-6-quantikine-elisa-kit-44202415433118.jpg)
![Immunocytochemistry EGR1 Antibody [Unconjugated]](https://images.novusbio.com/images/antibody/af2818_human-egr1-affinity-purified-polyclonal-ab-immunocytochemistry-3102024831..jpg)